Johnson & Johnson (JNJ) said Friday that data from a phase 3 study of Tremfya subcutaneous induction therapy in adults with moderately to severely active ulcerative colitis showed "statistically significant" and "clinically meaningful" improvements compared to a placebo.
The company said the results for the drug, also called guselkumab, were consistent with the intravenous induction regimen already approved last year by the US Food and Drug Administration.
At week 12, 26.6% of patients in the study treated with a 400 milligram dose showed clinical remission compared with 6.5% for the placebo while 65.6% showed a clinical response compared with 34.5% for the placebo, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。